Roche announced that it has received CE mark approval for its cobas Mass Spec solution including the cobas i 601 analyzer and the first Ionify reagent pack of four assays for steroid hormones.
The CE mark is the first milestone in the global launch of the cobas Mass Spec solution. Following launch, the cobas Mass Spec solution will roll out a menu offering of more than 60 analytes for testing of steroid hormones, vitamin D metabolites, immunosuppressant drugs (ISD), therapeutic drug monitoring (TDM) and drugs of abuse testing (DAT).
The cobas Mass Spec solution will be part of Roche’s established cobas pro integrated solutions.
